We have located links that may give you full text access.
Are there any challenges in HCV therapy of HIV infected patients left?
International Journal of Antimicrobial Agents 2018 August 24
Direct acting antivirals (DAAs) have tremendously improved treatment of Hepatitis C virus (HCV) infections also in Human immunodeficiency virus (HIV) positive individuals. Curing HCV is of particular importance in HIV positive individuals as liver disease progression is accelerated in the course of concomitant HIV infection. Former challenges, such as safety and tolerability as well as reduced treatment uptake of a peginterferon (pegIFN) and ribavirin (RBV) based treatment have been overcome with the approval of DAAs. Indeed, rates of discontinuation under modern all oral DAA therapy in HIV/HCV coinfection have been reported to be less than 1%. Rates of sustained virological response (SVR) after treatment have aligned with those seen in HCV monoinfected patients, resulting in an equalization of treatment recommendations for HCV monoinfected and HIV/HCV coinfected patients. Nevertheless, coinfection with HIV has been associated with slightly higher relapse-rates in some real-world cohorts, arousing a discussion concerning a more individualized treatment once again. Moreover, an ongoing epidemic of acute HCV infections in HIV positive MSM with high reinfection rates challenges physicians and researchers. A concise summary of the remaining challenges in HCV treatment of HIV positive individuals is given in the present review.
Full text links
Related Resources
Trending Papers
A Guide to the Use of Vasopressors and Inotropes for Patients in Shock.Journal of Intensive Care Medicine 2024 April 14
British Society for Rheumatology guideline on management of adult and juvenile onset Sjögren disease.Rheumatology 2024 April 17
Albumin: a comprehensive review and practical guideline for clinical use.European Journal of Clinical Pharmacology 2024 April 13
Renin-Angiotensin-Aldosterone System: From History to Practice of a Secular Topic.International Journal of Molecular Sciences 2024 April 5
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app